Simkhovich B Z, Przyklenk K, Kloner R A
Heart Institute, Good Samaritan Hospital, Los Angeles, CA, USA.
Cardiovasc Res. 1998 Oct;40(1):9-22. doi: 10.1016/s0008-6363(98)00142-4.
Protein kinase C (PKC) has been proposed as a primary cellular mediator of ischemic preconditioning. However, the role of PKC in eliciting cardioprotection remains controversial. In this review, we summarize the evidence for and against the 'PKC hypothesis' of preconditioning, discuss the important technical limitations currently hampering PKC research, and suggest new approaches (i.e. PKC isoform-specific biochemical assays combined with immunoblotting techniques) that might aid in the definite resolution of this issue.
蛋白激酶C（PKC）已被认为是缺血预处理的主要细胞介质。然而，PKC在引发心脏保护中的作用仍存在争议。在本综述中，我们总结了支持和反对预处理“PKC假说”的证据，讨论了目前阻碍PKC研究的重要技术局限性，并提出了可能有助于明确解决该问题的新方法（即PKC亚型特异性生化分析与免疫印迹技术相结合）。
